Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $33.00 to $34.00. They now have an "outperform" rating on the stock.
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Castle Biosciences Reports First Quarter 2024 Results [Yahoo! Finance]
Castle Biosciences Reports First Quarter 2024 Results